MANATEE Trial Study Centres in the UK Announced

15 November 2021

This global Phase 2/3 clinical study will evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth, in combination with risdiplam in SMA. It is due to start in February 2022. UK Centres taking part are Birmingham, GOSH, and Oxford.

The study will enroll 2 – 10-year-olds. Full details of eligibility and study design are on the clinical website.

If you are interested in enrolling your child, we suggest you discuss what would be involved with your child’s clinical team who will guide you further.